Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
15.40
+0.09 (0.59%)
Jan 5, 2026, 9:31 AM EST - Market open
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 134 employees as of December 31, 2024. The number of employees increased by 1 or 0.75% compared to the previous year.
Employees
134
Change (1Y)
1
Growth (1Y)
0.75%
Revenue / Employee
$1,354,761
Profits / Employee
$156,313
Market Cap
1.00B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 134 | 1 | 0.75% |
| Dec 31, 2023 | 133 | 10 | 8.13% |
| Dec 31, 2022 | 123 | 30 | 32.26% |
| Dec 31, 2021 | 93 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GLUE News
- 19 days ago - Why Is Monte Rosa Stock Trading Higher Today? - Benzinga
- 20 days ago - Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations - GlobeNewsWire
- 20 days ago - Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results - GlobeNewsWire
- 5 weeks ago - Monte Rosa: Looking Mispriced After Big Pharma Validation - Seeking Alpha
- 2 months ago - Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases - GlobeNewsWire